HIV- (n = 14) | IR (n = 18) | INR (n = 18) | p value | |
---|---|---|---|---|
T-CELL IMMUNE ACTIVATION | ||||
CD4+ T-cells | ||||
HLA-DR+ expression, % | 59 (16.2–92.9) | 61.8 (22.7–84.3) | 58.1 (37.3–75.8) | 0.949a |
HLA-DR+, MFI | 7500 (6646–10,826) | 9874 (5474–14,796) | 7067 (5591–13,789) | 0.802a |
CD38+ expression, % | 51.2 (42.9–56.1) | 47.3 (35.2–54.6) | 39.1 (25.3–42.7) | < 0.05a |
CD38+, MFI | 5203 (4322–6001) | 4771 (4574–5666) | 4930 (4475.5–5766.5) | 0.892a |
HLA-DR+ and CD38+ co-expression, % | 34.7 (31.9–52.3) | 40.8 (23.1–48.1) | 18.1 (9.8–23.8) | < 0.01a |
HLA-DR+ and CD38+, MFI | 11,380 (7002.5–12,585.5) | 5310 (4657–24,752) | 9661 (7280–18,114) | 0.727a |
CD8+ T-cells | ||||
HLA-DR+ expression, % | 37.8 (30.8–45.5) | 23 (13.4–57.9) | 35 (16.7–57.5) | 0.648a |
HLA-DR+, MFI | 7019.5 (5789–8557) | 10,965 (9207–17,730) | 9696 (7193.5–12,288.5) | < 0.05a |
CD38+ expression, % | 46 (33.2–50.4) | 33.6 (23–50.3) | 36.2 (24–43.4) | 0.618a |
CD38+, MFI | 4098 (3250–5171) | 3724 (3342–3791) | 3684 (3360–4640) | 0.712a |
HLA-DR+ and CD38+ co-expression, % | 11.1 (6.6–13.2) | 13.8 (11.6–15.8) | 12.4 (6.4–26.3) | 0.466a |
HLA-DR+ and CD38+, MFI | 8840 (7816–12,020) | 13,987 (10852–19,953) | 14,066 (11643–18,748) | 0.186a |
INNATE IMMUNE ACTIVATION | ||||
sCD14, ng/mL | 55.6 (12.2–199.6) | 184.7 (109.4–329.9) | 238.8 (196.2–378.9) | < 0.01a |
sCD163, ng/mL | 192.1 (158.3–254.9) | 242.5 (141.8–339.8) | 230.8 (94.5–385.9) | 0.789a |
SYSTEMIC INFLAMMATION | ||||
C-reactive protein, mg/dL | 0.27 (0.16–1.04) | 1.24 (0.67–2.09) | 1.63 (0.96–4.53) | < 0.05a |
C- reactive protein (≥ 3.0 mg/dL), N (%) | 1 (7.1%) | 3 (16.7%) | 6 (33.3%) | 0.168b |
MICROBIAL TRANSLOCATION | ||||
Lipopolysaccharide, pg/mL | 1098.7 (182.8–2876.2) | 588.6 (257.1–1931) | 979.2 (409.9–2281.8) | 0.644a |
PROINFLAMMATORY CYTOKINES | ||||
Fecal IL-1β, pg/mL | 10.4 (10.4–11.7) | 47.1 (16.9–114.4) | 44 (28.9–176.3) | < 0.001a |
Fecal IL-8, pg/mL | 8.21 (8.2–16.6) | 116.8 (21.9–234.7) | 88.7 (43.8–204.5) | < 0.001a |
Fecal IL-18, pg/mL | 40.7 (40.7–40.7) | 66.8 (40.7–487) | 132.8 (40.7454.6) | < 0.01a |
IL-1β, pg/mL | 11.1 (10.4–11.8) | 11.8 (10.4–16.9) | 16.9 (10.4–21.9) | 0.368a |
IL-8, pg/mL | 16.58 (8.2–22) | 16.6 (8.21–22) | 16.6 (8.2–27.3) | 0.845a |
IL-18, pg/mL | 89.7 (40.7–192.2) | 158 (96.2–257.7) | 173.4 (96.2–316.12) | 0.153a |
INTESTINAL DAMAGE | ||||
I-FABP, ng/mL | 6.33 (0.0–126.4) | 31.2 (8.5–283.2) | 53.6 (27.3–216.2) | 0.164a |
sST2, ng/mL | 28.6 (23.6–35.6) | 31.1 (23.4–39.3) | 33.1 (27.6–38.5) | 0.603a |
INTESTINAL INFLAMMATION | ||||
Fecal lactoferrin, μg/g | 2.0 (1.8–2.5) | 2.5 (1.9–2.9) | 3.1 (2.2–4.0) | < 0.05a |
Fecal lactoferrin (≥ 5.6 μg/g), N (%) | 0 (0%) | 1 (5.6%) | 3 (17%) | 0.202b |
Fecal calprotectin, μg/g | 2.7 (2.6–2.9) | 2.7 (2.6–2.9) | 3.1 (2.7–3.4) | < 0.05a |
Secretory IgA, mg/L | 8566.5 (5066.9–10,042.2) | 10,122.1 (5721–10,844.8) | 7791.2 (6257.4–11,329.9) | 0.82a |